Antiplatelet Drug

PreclinicalSmall molecule

FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Antiplatelet Drug is one of 158 small molecule programs targeting Cardiac Arrest. It is currently in Preclinical.

Indications

Total Trials

Active Trials

157

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cardiac ArrestActive, not recruiting

StrokeActive, not recruiting

Type 2 DiabetesActive, not recruiting

Subarachnoid HemorrhageActive, not recruiting

Myocardial InfarctionActive, not recruiting

Cardiac ArrestPreclinical

Active, not recruiting

StrokePreclinical

Active, not recruiting

Type 2 DiabetesPreclinical

Active, not recruiting

Subarachnoid HemorrhagePreclinical

Active, not recruiting

Myocardial InfarctionPreclinical

Active, not recruiting

Competition

Competitive Landscape

171 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

NOVOLIN R

Novo Nordisk

Preclinical

5 2

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 3

Aurlumyn

BBTG International Inc.

Preclinical

1 4

Nexium

DDexcel Pharma Technologies Ltd.

Preclinical

1 5

Inderal

WWyeth-Lederle Vaccines

Preclinical

1 6

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

1 7

SGLT-2 Inhibitor

SSheffield Teaching Hospitals NHS Foundation Trust

Preclinical

2 8

Routine Treatment

GSK

Preclinical

1 9

Sulfonylureas

Eli Lilly

Preclinical

1 10

Antiplatelet Drug

FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

ApprovedActive, not recruiting

Antiphospholipid Syndrome

NCT05995600

Clinical

Trials by Indication[1]

Atrial Fibrillation1 trial

Optimal Antithrombotic Therapy in Ischemic Stroke Patients with Non-Valvular Atrial Fibrillation and Atherothrombosis

Terminated·NNational Hospital Organization Osaka National Hospital·Phase 4·NCT03062319·321 enrolled

Myocardial Infarction1 trial

Targeting Investigation and Treatment in Patients With Type 2 Myocardial Infarction

Completed·UUniversity of Edinburgh·N/A·NCT05419583·60 enrolled

Subarachnoid Hemorrhage1 trial

Effect of Antiplatelet Therapy on Cognition After Aneurysmal Subarachnoid Hemorrhage

Unknown status·NNanjing Medical University··NCT04548401·200 enrolled

Antithrombotic1 trial

REGistry of Long-term AnTithrombotic TherApy-1

Recruiting·NNational Medical Research Center for Cardiology, Ministry of Health of Russian Federation··NCT04347200·2,000 enrolled

Cardiac Arrest1 trial

Monitoring Antiplatelet Drugs in Cardiac Arrest Patients

Unknown status·UUniversity of Milano Bicocca··NCT05730114·60 enrolled

6 more indications

Trial1 trial

Prognostic Value of Precision Medicine in Patients With MINOCA (PROMISE Trial).

Active, not recruiting·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·Phase 4·NCT05122780·120 enrolled

Stroke1 trial

Carotid Web and Stroke Registry.

Unknown status·FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau··NCT05475080·100 enrolled

Carotid Stenosis1 trial

Smart Nitinol Stent System for the Treatment of Severe Atherosclerotic Carotid Stenosis

Completed·—·N/A·NCT02800174·103 enrolled

Type 2 Diabetes1 trial

Type 2 Diabetes With Antiplatelet Drugs

Completed·TTabula Rasa HealthCare··NCT05053828·173,464 enrolled

Antiphospholipid Syndrome1 trial

Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin as Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE (APS-STROKE)

Active, not recruiting·SSeoul National University Hospital·Approved·NCT05995600·200 enrolled

Unspecified1 trial

LEADERS FREE II: BioFreedom™ Pivotal Study

Active, not recruiting·BBiosensors Europe SA·N/A·NCT02843633·1,203 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Antiplatelet Drug. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Antiplatelet Drug compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Antiplatelet Drug. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Antiplatelet Drug

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Atrial Fibrillation1 trial

Myocardial Infarction1 trial

Subarachnoid Hemorrhage1 trial

Antithrombotic1 trial

Cardiac Arrest1 trial

Trial1 trial

Stroke1 trial

Carotid Stenosis1 trial

Type 2 Diabetes1 trial

Antiphospholipid Syndrome1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News